Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Xencor Receives Janssen R&D Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Xencor Receives Janssen R&D Milestone

Will use Xtend technology for therapeutic antibody

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Xencor, Inc. has received a milestone payment from Janssen R&D for the use of Xencor’s Xtend half-life extension technology in a therapeutic antibody. The companies had entered a technology license agreement in 2009. The antibody target and payment amount were not disclosed.
 
“There has been significant interest in Xtend technology because of the impact it has on the pharmacokinetic properties of antibodies, and we are seeing Xencor technology license agreements with partners translate into promising pipeline programs,” said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics